Bioequivalence of two fluoxetine capsules, the $Prozac^{circledR}$ (Daewoong Lilly Pharmaceutical Co., Ltd.) and the $Lucetin^{circledR}$ (Kyungdong Pharmaceutical Co., Ltd.), was evaluated according to the guideline of KFDA. Twenty normal male volunteers $(21{sim}30;years;old)$ were divided into two groups and a randomized $2{ imes}2$ cross-over study was employed. After three capsules containing 20 mg of fluoxetine per capsule were orally administered, blood was taken at predetermined time intervals, and the concentrations of fluoxetine in serum were determined using HPLC method with UV detector. The pharmacokinetic parameters ($AUC_t$, $C_{max}$ and $T_{max}$) were calculated and ANOVA test was utilized for the statistical analysis of parameters. The results showed that the differences in $AUC_t$, $C_{max}$ and $T_{max}$ between two capsules based on $Lucetin^{circledR}$ capsules were -8.01 %, -7.02% and 1.49%, respectively. The powers $(1-{eta})$ for $AUC_t$, $C_{max}$ and $T_{max}$ were 84.72%, 96.68% and 83.06%, respectively. Detectable differences $({Delta})$ and confidence intervals were all less than ${pm}20%$. All the parameters above met the criteria of KFDA for bioequivalence, indicating that $Lucetin^{circledR}$ capsule is bioequivalent to $Prozac^{circledR}$ capsule.